Skip to main content
OpenTrials
Completed

NCT Number: NCT03017521

K-BASKET, TAS-117, PI3K/AKT Gene Aberration

The phosphatidylinositol 3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) signaling pathway is one of the most frequently aberrantly regulated pathways in human tumors. TAS-117 is a highly potent and selective oral allosteric AKT inhibitor. It has high affinity for AKT1, 2, and 3 and shows potent anti-proliferative activity against multiple tumor cell lines in vivo. Therefore, we propose to conduct a phase II trial of TAS-117, potent and selective AKT inhibitor, in patients with advanced solid tumor with PI3K/AKT genetic aberrancy by NGS focusing panel in part of K-BASKET trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumor, Adult

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically or cytologically confirmed recurrent or advanced solid cancers with PI3K/ATK aberration
  • Progressive disease who failed to previous standard treatment.
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria
  • Eastern Cooperative Oncology Group performance status 0 or 1
  • Able to take medications orally
  • Adequate organ function
  • A life expectancy of at least 60 days

Exclusion criteria

  • Previous treatment with anti-PI3K or AKT directed therapies
  • Known hypersensitivity to any drugs similar to TAS-117 in structure or class.
  • History or current evidence of type 1 or type 2 diabetes mellitus that requires insulin and/or oral antidiabetic therapy.
  • Current evidence of retinopathy that requires ophthalmological therapy.
  • History or current evidence of cardiac arrhythmia and/or conduction abnormality.
  • Treatment with any of the following within the specified time frame prior to study drug administration:
  • Major surgery within prior 4 weeks
  • Radiation therapy for extended field within 4 weeks prior to study drug administration or limited field radiation therapy within 2 weeks prior to study drug administration.
  • Any anticancer treatment within 3 weeks prior to study drug administration (mitomycin within prior 5 weeks).
  • A serious illness or medical condition(s)
  • Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding alopecia, skin pigmentation and anemia).
  • Patients with the risk of hypokalemia
  • Receiving oral steroid medication.
  • Pregnant or lactating female

Treatment and study plan

TAS-117

Drug

TAS-117 16mg, daily

Primary outcomes

  1. overall response rate

    Time frame: 2 months

Sponsors and collaborators

Lead sponsor

Yonsei University

Other

Registry information

Official study title

A Phase II Study of TAS-117 in Advanced Solid Tumors With PI3K/AKT Gene Aberration (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial)

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jan 11, 2017
Registry last updated
Apr 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.